The expression and activation of the AIM2 inflammasome correlates with inflammation and disease severity in patients with acute pancreatitis.
Por:
Algaba-Chueca F, De madaria E, Lozano B, Martínez C, Quesada N, Bachiller V, Tarin F, Such J, Frances R, Zapater P and Gonzalez J
Publicada:
1 may 2017
Resumen:
Acute pancreatitis is an inflammatory disorder of the pancreas that is responsible for significant morbidity and mortality. The inflammasome pathway has acquired significant relevance in the pathogenesis of many inflammatory disorders, but its role in patients with acute pancreatitis still awaits clarification.
Filiaciones:
Algaba-Chueca F:
Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Institute of Health Carlos III, Madrid, Spain
De madaria E:
Alicante Institute of Health and Biomedical Research (ISABIAL - FISABIO Foundation), Alicante, Spain
Department of Gastroenterology, General Hospital of Alicante, Alicante, Spain
Lozano B:
Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Institute of Health Carlos III, Madrid, Spain
Alicante Institute of Health and Biomedical Research (ISABIAL - FISABIO Foundation), Alicante, Spain
Martínez C:
Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Institute of Health Carlos III, Madrid, Spain
Department of Pharmacology, University Miguel Hernández, Alicante, Spain
Quesada N:
Alicante Institute of Health and Biomedical Research (ISABIAL - FISABIO Foundation), Alicante, Spain
Department of Gastroenterology, General Hospital of Alicante, Alicante, Spain
Bachiller V:
Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Institute of Health Carlos III, Madrid, Spain
Tarin F:
Hematology Service, General Hospital of Alicante, Alicante, Spain
Such J:
Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Institute of Health Carlos III, Madrid, Spain
Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Frances R:
Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Institute of Health Carlos III, Madrid, Spain
Alicante Institute of Health and Biomedical Research (ISABIAL - FISABIO Foundation), Alicante, Spain
Department of Clinical Medicine, University Miguel Hernandez, Alicante, Spain
Zapater P:
Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Institute of Health Carlos III, Madrid, Spain
Alicante Institute of Health and Biomedical Research (ISABIAL - FISABIO Foundation), Alicante, Spain
Department of Pharmacology, University Miguel Hernández, Alicante, Spain
Gonzalez J:
Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Institute of Health Carlos III, Madrid, Spain
Alicante Institute of Health and Biomedical Research (ISABIAL - FISABIO Foundation), Alicante, Spain
|